1. Lozada C, Steigelfest E. Osteoarthritis. Medicine Rheumatology 2010; 15:12-23.
2. Raynauld JP, Martel-Pelletier J, Haraoui B, Pelletier JP. Chapter 25. Osteoarthritis-arthrosis short term studies: pain and function improvement in osteoarthritis 2002, pages 294 – 306.
3. Garstang SV, Stitik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil 2006; 85:s2–s11.
4. Tsumura H, Tamura I, Tanaka H, et al. Prescription of non-steroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopaedists in japan. Inter Med. 2007; 46:927-931.
5. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis. part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis cartilage 2007; 15: 981-1000.
6. Bierma-zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol. 2007; 3:78-85.
7. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007; 213: 626–634.
8. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 2004; 12 (suppl a):s31–s33.
9. Chevalier X, Mugnier B, Bouvenot G, Chevalier X, Mugnier B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis]. [review] Bull Acad Nationale Medecine. 2006; 190:1411–1420.
10. Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Reumatol. 2006; 20:81-97.
11. Lee YC, Shmerling RH. The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis. Curr Rheumatol Rep. 2008; 10:5-10.
12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI Recommendations for the management of hip and knee osteoarthritis. part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007; 15:981–1000.
13. Zhang W, Moskowitz R, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16: 137-162.
14. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2006, 20:117-129.
15. Kobayakawa M, Uemura N. Prevention and treatment of non-steroidal anti-inflammatory drugs induced ulcers in osteoarthritis. Nippon Rinsho 2007, 65: 1857-1861.
16. Scanzello CR, Moskowitz NK, et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep. 2008; 10:49-56.
17. Mikhail SS, Zwar NA, Vagholkar S, Dennis SM, Day RO. Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. Med J Aust. 2007; 187: 160-163.
18. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term nsaid therapy in orthopaedic outpatients: a study using logistic regression analysis. J Orthop Sci 2007, 12: 341-346.
19. Mitchell J., Warner T. Discontinuation of Vioxx. The Lancet 2004, 365,9453: 27-28.
20. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-81.
21. Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-64.
22. Lamarque D. Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Gastroenterol Clin Biol. 2004, 28: C18-26.
23. Whittle BJ. Gastrointestinal effects of non-steroidal anti-inflammatory drugs. Fundam Clin Pharmacol. 2003;17:301–313.
24. Kountouras J, Chatzopoulos D, Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology 2001, 48: 743 – 751.
25. Demir S, Yilmaz M, Koseoglu M, Akalin N, Aslan D, Aydin A. Role of free radicals in peptic ulcer and gastritis. Turkish J. Gastroenterology, 2003. 14:39-43.
26. Pohle T, Brzozowski T, Becker JC, Van Der Voort IR, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther. 2001; 15:677–687.
27. Lin J., Zhang W. et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004;329:324.
28. Cepeda MS, Camargo F. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006; CD005522.
29. Towheed TE, Maxwell L, Judd M, Cotton M, Huchberg MC, Wells GA. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006; January 25 (1):CD004257.
30. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009; 37:1636-1644.
31. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
32. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
33. McAlindon T: Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am 2003, 29:789-801.
34. McAlindon TE, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004, 117:643-649.
35. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res. 2008; 36:1161-1179.
36. Piscoya J, Rodríguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001, 50:442-448.
37. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med 2002, 33:1097-1105.
38. Walter-Bone K: 'Natural remedies' in the treatment of osteoarthritis. Drugs & Aging 2003, 20:517-526.
39. Miller M, Mehta K, Kunte S, et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial. J Inflamm. 2005; 2:11-17.
40. Frestedt JL, Walsh M, Koskowski M, Zenk J. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized, controlled pilot trial. Nutrition J. 2008; 7:9-13.
41. Cisar P. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytoher Res. 2008; 22: 518-523.
42. Frech TM, Clegg DO. The utility of nutraceuticals in the treated of osteoarthritis. Rheumatol Rep. 2007; 9:25-30.
43. Mas R. Abexol: Beeswax alcohols. Drugs of the Future. 2001; 26:731-744.
44. Menéndez R., Amor AM, González RM, et al. Inhibition of rat microsomal lipid peroxidation by the oral administration of Abexol. Brazil J Med Biol Res. 2000; 33: 85-90.
45. Molina V, Valdés S, Carbajal D, et al. Antioxidant effects of Abexol on gastric mucosa of rats with injury induced experimentally. J Med Food. 2001; 4: 79-84.
46. Pérez Y, González R, Amor AM, et al. Abexol on antioxidant enzymes in liver and brain of rats. Rev CENIC Cien Biol. 2002; 33:3-5.
47. Mendoza S, Noa M, Perez Y, Más R. Preventive effect of Abexol, a mixture of long-chain alcohols from beeswax, on the liver damage induced with CCl4 in rats. J Med Food. 2007;10: 379-383.
48. Menéndez R, Más R, Amor AM, et al. Antioxidant effects of Abexol on the in vitro susceptibility in healthy volunteers. Arch Med Res. 2001; 32: 436-441.
49. Menéndez R, Más R, Illnait J, et al. Effects of Abexol on lipid peroxidation in older subjects. J Med Food. 2001; 4: 71-77.
50. López E, Illnait J, Molina V, et al. Effects of Abexol (beeswax alcohols) on lipid peroxidation in middle-aged and older subjects. LAJP. 2008; 27: 695-703.
51. Rodriguez I, Illnait J, Molina V, et al. Comparison of the antioxidant effects of Abexol (beeswax alcohols) and grape seed extract (GSE) on plasma oxidative variables in healthy subjects LAJP. 2009,4:21-26.
52. Pérez Y, Oyarzábal A, Ravelo Y, Mas R, Jiménez S, Molina V. Inhibition of COX and 5-LOX enzymes by D-002 (beeswax alcohols). Current Top Nutraceutical Research. 2012.
53. Carbajal D, Molina V, Valdés S, et al. Anti-inflammatory activity of Abexol: an active product isolated from beeswax. Prostag Leuk Essent Fatty Acids. 1998;59:235-238.
54. Ravelo Y, Molina V, Carbajal D, et al. Effects of single oral and topical administration of D-002 (beeswax alcohols) on xylene induced ear edema in mice. LAJP 2010, 29.
55. Ravelo Y, Molina V, Carbajal D, et al. Evaluation of anti-inflammatory and antinociceptive effects of Abexol (beeswax alcohols). J Nat Med. 2010; 65:330-335.
56. Carbajal D, Molina V, Valdés S, et al. Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Phamacol 1995, 47: 731-733.
57. Carbajal D, Molina V, Valdés S, et al. Possible cytoprotective mechanism in rats of Abexol an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol. 1996;48:858-860.
58. Carbajal D, Molina V, Noa M, et al. Effects of Abexol on gastric mucus composition in ethanol induced ulcer. Pharmacol Res. 2000; 42:329-332.
59. Illnait J, Terry H, Más R, et al. Effects of Abexol, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: a pilot study. J Med Food. 2005; 8:63-68.
60. Rodríguez I, Illnait J, Terry H, et al. Effects of Abexol (beeswax alcohols) on the gastrointestinal symptoms of middle-aged and elderly subjects. Rev CENIC Cien Biol. 2009; 40:3-8.
61. Hano O, Illnait J, Más R, et al. Effects of Abexol, a product isolated from beeswax, on duodenal ulcer: A double-blind, placebo-controlled study. Curr Ther Res. 2001; 62:394-407.
62. Fernández JC, Rodríguez I, Illnait J, Fernández L, Mas R, Pérez Y, Gámez R, Mesa M, Jiménez S, Mendoza S, Ruiz D. Effects of Abexol (beeswax alcohols) in patients with gastric symptoms. Rev CENIC Cien Biol 2012;43(1):9-16.
63. Fernández L, Terry H, Quiñones AM, et al. Effects of Abexol in middle-aged and older subjects: an open follow-up. Rev CENIC Cien Biol. 2008; 39:3-8.
64. Rodeiro I, Alemán C, Noa M, et al. Preclinical oral toxicology in rats of Abexol, a natural drug with antiulcer effects. Drug Chem Tox. 1998; 21:151-163.
65. Rodeiro I, Gámez R, Acosta PC, et al. Estudio genotoxico del Abexol, un producto con actividad antiulcerosa Rev Esp Tox. 1998; 15:117-121.
66. Rodríguez MD, Gámez R, Sánchez M, García H. Developmental toxicity of Abexol, a mixture of aliphatic primary alcohols in rats and rabbits. J Appl Toxicol. 1998; 18:313-316.
67. Rodeiro I, Alemán C, Noa M, et al. Oral toxicological studies of Abexol in mice. Rev CENIC Cien Biol. 1999;30:73-75.
68. Alemán C, Rodeiro I, Noa M, et al. A one-year study of Abexol. a mixture of aliphatic primary alcohols in Beagle dogs. J Appl Toxicol. 2000; 20:427-432.
69. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs of the Future 2004, 29: 773-786.
70. Menéndez R, Mas R, Pérez Y et al: Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol 2002, 80: 13-17.
71. Pérez Y, Menéndez R, Mas R et al: Efectos de la administración oral de D-003 sobre la peroxidación lipídica “in vivo” e “in vitro” en hígados de ratas. Rev Cubana Farmacia 2002, 36 (Suppl 2), 80-85.
72. Pérez Y., Mas R., González RM., Jiménez S., Molina V. Effects of D-003 and policosanol on in vivo lipid peroxidation in rats. Arzn-Forsch Drug Res 2008, 58: 126- 130.
73. Noa M., Mendoza S., Más R., Mendoza N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on CL4C-induced liver acute injury in rats. Drugs Exp Clin Res 2002, 28: 177-183.
74. Castaño G., Menéndez R., Más R., Ledón N., Fernández JC, Pérez JL., González RM., Lescay M. Effects of D-003: A new hypocholesterolaemic and antiplatelet compound on lipid profile and lipid peroxidation in healthy volunteers , Clin Drug Invest 2003 , 23 (3): 193-203.
75. Pérez Y., Menéndez R., Mas R.,, González RM., Fernández L., Fernández JC., Illnait J., Mendoza S.. Effects of D-003, a mixture of high molecular weight acids from sugarcane wax, on lipid peroxidation (LP) markers of older individuals. Curr Ther Res 2008, 69 (1): 36-48.
76. Noa M, Mendoza S, Más R, et al. Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague Dawley rats. Drugs R D 2004; 5 : 281-290.
77. Mendoza S, Noa M, Mas R, Mendoza N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on liver damage induced by paracetamol in rats. Int J Tissue Reaction 2003, 25: 91-98.
78. Noa M, Mendoza S, Mas R. Lack of protective effect of D003, a mixture of high molecular weight primary acids from sugar cane wax, on liver damage induced by galactosamine in rats. J Med Food 2005, 8: 343-347.
79. Noa M., Más R., Mendoza S, et al. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats. Drugs Exptl Clin Res 2004, 30: 35 – 41.
80. Mendoza S, Noa M, Más R, Mendoza N. Effects of D-003 (5 – 200 mg/kg), a mixture of high molecular weight aliphatic acids from sugarcane wax, on bones and bone cell apoptosis in ovariectomized rats. Int J Tiss React 2005, XXVII: 213-222.
81. Mendoza S, Noa M, Mas R. A comparison of the effects of D-003, a mixture of high molecular weight aliphatic acids from sugarcane wax, and pravastatin, on bones and osteoclast apoptosis of ovariectomized rats. Drugs Exp Clin Res 2005, 31: 181-191.
82. Noa M, Mendoza S, Mas R, Mendoza N, Goicochea E. Long term effects of D-003, a mixture of high molecular weight acids from sugarcane wax, on bones of ovariectomized rats: a one year study. Die Pharmazie 2008, 63: 486-488.
83. Ceballos A., Mas R., Castaño G., et al. The effect of D-003 (10 mg/day) on biochemical parameters of bone remodelling in postmenopausal women: a randomized, double-blind study. Int J Clin Pharmacol Res. 2005; 25: 175-186.
84. Ceballos A, Castaño G, Mendoza S, González J, Mas R, Fernández L, Illnait J, Mesa M, Gámez R, Fernández JC, Telles R, Marrero D, Gómez M, Ruiz D, Jardines Y Effect of D-003 (10 mg/day) on the bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study. Korean J Intern Med. 2011; 26(2): 168–178.
85. Mendoza S, Noa M, Valle M, Mendoza N, Mas R. Effects of D-003 on formaldehyde induced osteoarthritis in rats. Int J Pharm Sci 2012.
86. Mendoza S, Noa M, Valle M, Mendoza N, Mas R. D-003, a mixture of sugar cane wax acid, reduces joint damage in mia induced osteoarthritis in rats. Int J Pharm Sci 2012.
87. Perez Y, Oyarzábal A, Mas R, Jiménez S, Molina V. Effects of policosanol (sugar cane wax alcohols) and D-003 (sugarcane wax acids) on ciclooxygenase (COX) enzyme activity in vitro. Curr Top Nutr Res 2012.
88. Gámez R, Más R, Noa M et al: Acute and subchronic oral toxicity of D-00– in rats. Toxicol Letters 2000, 118: 31 - 41.
89. Gámez R, Mas R, Noa M et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs in R&D 2002, 3: 375 – 386.
90. Gámez R, Más R, Noa M et al: Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle–dogs. Drugs Exp & Clin Res 2004, 30: 75-88.
91. Gámez R, González JE, Rodeiro I et al. In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic alcohols. J Med Food 2001, 4: 85-92.
92. Gámez R, Rodeiro I, Fernández I, Acosta P. Preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog, Carcinog, Mutagenesis 2002, 22: 175-181.
93. Rodríguez MD, Gámez R, González JE et al. Lack of developmental toxicity of D-003: a mixture of long-chain fatty acids in rats. Fd Chem Toxicol 2003, 41: 89–93.
94. Rodríguez MD, González JE, Aleman C et al. Evaluation of the reproductive and developmental toxicity of D-003, a mixture of long-chain fatty acids, in rats and–rabbits. Fd Chem Toxicol 2004, 42: 1977-1985.
95. Rodríguez MD, Gutiérrez A, Marrero G, García H. Perinatal/postnatal study of D-003, a mixture of long-chain fatty acids in rats. J Med Food 2006, 9: 223–230.
96. Gámez R, Noa M, Mas R, et al. Long-term carcinogenicity of D-003, a mixture of high molecular weight acids from sugarcane wax, in Sprague Dawley rats: a 24 months study. Food Chem Tox 2007, 45:2352-2358.
97. Batlle-Gualda E, Esteve-Vives J, Piera MC, Hargreaves R, Cutts J. Adaptación transcultural al cuestionario WOMAC especifico para artrosis de rodilla y cadera. Rev Esp Reumatol. 1999; 26:38-45.
98. Angst T, Aeschlimann A, Stuki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implication for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis and Rheumatism. 2001; 45:384-391.
99. Altman R, Asch E, Bloch D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986, 9:1039-1049.
100. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505 – 514.
101. Requerimientos para la notificacion y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. Regulacion No. 45-2007. CECMED, 2007.
102. O’Brien P.C, Shampo M.C. Statistical considerations for performing multiple tests in a single experiment 5. Comparing two therapies with respect to several endpoints. Mayo Clin Proc. 1988, 63: 1140-1143.
103. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol. 2007; 3:78-85.
104. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res. 2008; 36:1161-1179.
105. Piscoya J, Rodríguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res. 2001, 50:442-448.
106. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med. 2002, 33:1097-1105.
107. Walter-Bone K. 'Natural remedies' in the treatment of osteoarthritis. Drugs & Aging. 2003, 20:517-526.
108. Miller M, Mehta K, Kunte S, et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial. J Inflamm. 2005; 2:11-17.
109. Frestedt JL, Walsh M, Koskowski M, Zenk J. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized, controlled pilot trial. Nutrition J. 2008; 7:9-13.
110. Cisar P. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytoher Res. 2008; 22: 518-523.
111. Frech TM, Clegg DO. The utility of nutraceuticals in the treated of osteoarthritis. Rheumatol Rep. 2007; 9:25-30.
112. Scanzello CR, Moskowitz NK, et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep. 2008; 10:49-56.
113. Rodríguez I, Illnait J, Mendoza S, Fernández L, et al. Effects of D-002, amixture of beeswax alcohols, on osteoarthritis symptoms: a randomized placebo-controlled study. Journal of Pharmacy. 2012, 2 (6).
114. Puente R. Illnait J, Mendoza S., Fernández J, et al. Estudio de los efectos antii-nflamatorios del prevenox en sujetos con síntomas de ostroartritis. 2012. Datos de archivo.